5-Amino-1MQ (50mg)
5-Amino-1MQ dosing protocols center on this selective NNMT inhibitor studied for supporting fat metabolism, preserving lean mass, and increasing intracellular NAD+ levels. This protocol outlines a subcutaneous approach using the larger 50 mg vial for extended use.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full 5-Amino-1MQ encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
5-Amino-1MQ selectively inhibits Nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide, depleting NAD+ availability. By inhibiting NNMT, it conserves nicotinamide for NAD+ synthesis, activating SIRT1 pathways related to mitochondrial biogenesis and fat oxidation. Preclinical studies show that NNMT inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake.
Quick Start
- Reconstitution: Add 4.0 mL bacteriostatic water → 12.5 mg/mL concentration.
- Typical daily range: 2.5–5 mg once or twice daily (subcutaneously).
- Storage: Lyophilized: freeze at −20 °C; post-reconstitution, refrigerate at 2–8 °C; use within 2–4 weeks.
Subcutaneous Protocol (4 mL = 12.5 mg/mL)
Route: Subcutaneous | Frequency: Once or twice daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Days 1–2 (Tolerance) | 2.5 mg once | 20 Units (0.20 mL) |
| Days 3+ (Typical) | 5 mg once | 40 Units (0.40 mL) |
| Alternative BID | 2.5 mg twice | 20 Units (0.20 mL) |
Studies report administration once or twice daily subcutaneously. Plasma half-life ~3.8–6.9 hours; BID dosing provides more stable NNMT inhibition. One 50 mg vial provides 10–20 days of research material.
Related compounds
Reconstitution Steps
- Remove from freezer and let equilibrate for 15–20 minutes.
- Withdraw 4.0 mL bacteriostatic water.
- Inject slowly down the side; avoid foaming.
- Gently swirl until dissolved (do not shake vigorously).
- Label and refrigerate at 2–8 °C; use within 2–4 weeks.
Protocol Overview
- Goal: Support metabolic efficiency via NNMT inhibition.
- Schedule: Daily subcutaneous injections; each 50 mg vial provides 10–20 days.
- Storage: Lyophilized frozen; reconstituted refrigerated.
Dosing Protocol
- Initiation: 2.5 mg once daily to assess tolerance.
- Target: 5 mg once or 2.5 mg twice daily.
- Frequency: Once or twice daily (subcutaneously).
- Vial Duration: 10–20 days at research doses.
- Timing: Morning administration; BID: morning/afternoon.
- Break between cycles: Post-cycle, a washout period of 2–4 weeks is recommended. NNMT inhibition modulates NAD+ levels—a break prevents metabolic adaptation.
Washout & Cycle Restart
When can I restart?
Post-cycle, a washout period of 2–4 weeks is recommended. NNMT inhibition modulates NAD+ levels—a break prevents metabolic adaptation.
Minimum wait period: 2 weeks
Storage Instructions
- Lyophilized: Store at −20 °C; stable up to 24 months.
- Reconstituted: Refrigerate 2–8 °C; use within 2–4 weeks.
- Allow to reach room temperature before reconstitution.
- Do not re-freeze reconstituted solution.
Important Notes
- The 50 mg vial is ideal for extended research protocols.
Potential Benefits & Side Effects
Potential Benefits:
- May support fat mass reduction while preserving lean muscle tissue in animal models.
- Associated with increased NAD+ levels and SIRT1 activation.
- Enhanced grip strength in aged mice when combined with exercise.
- Generally well-tolerated; mild headache or injection site reactions.
- Long-term human safety data is not established.
Potential Side Effects:
- Nausea or stomach discomfort (mild, initial).
- Headache (transient).
- Fatigue during metabolic adaptation.
- Dry mouth or increased thirst.
- Potential hypoglycemia due to NNMT inhibition.
- Limited long-term human safety data.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Hepatotoxicity (preclinical)
As an NNMT inhibitor, 5-amino-1MQ has shown hepatotoxicity at high doses in rodents. No human safety studies exist.
📄 Biochem Pharmacol 2020References
- Nature Medicine (2014) — NNMT inhibition and protection from obesity
View Source - PMC (2024) — NNMT inhibition mitigates metabolic dysfunctions
View Source - Frontiers in Pharmacology (2024) — NNMT: therapeutic target for metabolic syndrome
View Source - PubMed (2021) — Pharmacokinetics of 5-amino-1-methylquinolinium
View Source - Journal of Medicinal Chemistry (ACS) — NNMT inhibitors with enhanced potency
View Source
External Sources & Regulatory Status
Regulatory Approvals
Research-only — NNMT inhibitor
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →